Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Feb 4;3(1):42-4.
doi: 10.5492/wjccm.v3.i1.42.

Failure of lorazepam to treat alprazolam withdrawal in a critically ill patient

Gaurav Sachdev  1 , Gail Gesin  1 , A Britton Christmas  1 , Ronald F Sing  1
Affiliations
Case Reports

Failure of lorazepam to treat alprazolam withdrawal in a critically ill patient

Gaurav Sachdev et al. World J Crit Care Med. .

Abstract

Management of sedation in the critical care unit is an ongoing challenge. Benzodiazepines have been commonly used as sedatives in critically ill patients. The pharmacokinetic and pharmacodynamic properties that make benzodiazepines effective and safe in critical care sedation include rapid onset of action and decreased respiratory depression. Alprazolam is a commonly used benzodiazepine that is prescribed for anxiety and panic disorders. It is frequently prescribed in the outpatient setting. Its use has been reported to result in a relatively high rate of dependence and subsequent withdrawal symptoms. Symptoms of alprazolam withdrawal can be difficult to recognize and treat in the critical care setting. In addition, other benzodiazepines may also be ineffective in treating alprazolam withdrawal. We present a case of alprazolam withdrawal in a critically ill trauma patient who failed treatment with lorazepam and haloperidol. Subsequent replacement with alprazolam resulted in significant improvement in the patient's medication use and clinical status.

Keywords: Alpralazom; Lorazepam; Pharmacodynamics; Pharmacokinetics; Withdrawal.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Dosages of lorazepam and clonazepam: hospital days 2-11.
See this image and copyright information in PMC

References

    1. Barr J, Fraser GL, Puntillo K, Ely EW, Gélinas C, Dasta JF, Davidson JE, Devlin JW, Kress JP, Joffe AM, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41:263–306. - PubMed
    1. Klein E. The role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation with a focus on extended-release alprazolam. J Clin Psychiatry. 2002;63 Suppl 14:27–33. - PubMed
    1. Trevor AJ, Way WL. Sedative-hypnotic drugs. In: Katzung BG, editor. Basic and Clinical Pharmacology, 6th edition. East Norwalk, CT: Appleton & Lange; 1995. pp. 333–349.
    1. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004;65 Suppl 5:7–12. - PubMed
    1. Patterson JF. Withdrawal from alprazolam dependency using clonazepam: clinical observations. J Clin Psychiatry. 1990;51 Suppl:47–49; discussion 50-53. - PubMed

Publication types

LinkOut - more resources